Skip to content
Search

Latest Stories

Submit Guest Post

India, UK commit to free trade deal

India and the UK have affirmed their commitment to negotiate a free trade agreement (FTA) with a view to further strengthen economic ties, the commerce ministry said on Saturday.

The issue was discussed in the 14th Joint Economic and Trade Committee (JETCO) meeting between the two countries on Friday. It was co-chaired by commerce and industry minister Piyush Goyal and UK secretary of state for international trade Elizabeth Truss.


They were assisted by minister of state for commerce and industry Hardeep Singh Puri and his UK counterpart Ranil Jayawardena.

Goyal and Truss "affirmed their shared commitment to an FTA and towards that, Early Harvest deals in a staged manner," the ministry said in a statement. It added that Puri and Jayawardena will have monthly meetings to intensify the dialogue.

It was also decided that a meeting led by Goyal and Truss will be held in Autumn 2020 here to carry forward the dialogue.

In an FTA, two trading partners eliminate or significantly reduce import duties on the maximum number of goods traded between them.

The statement also said that the co-chairs of business led Joint Working Groups on life science and health, ICT and food and drink set up during the last JETCO made their recommendations to the ministers.

"Both sides resolved to cooperate in the health sector especially in view of the present pandemic of COVID-19," it said.

The bilateral trade between the two countries stood at $5.5 billion in 2019-20 as against $16.87 billion in 2018-19.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less